ACHL Stock Summary and Trading Ideas (Achilles Therapeutics PLC - American Depositary Shares | NASDAQ:ACHL)

Achilles Therapeutics PLC is a biopharmaceutical company. It is developing AI-powered precision T-cell therapies targeting clonal neoantigens to treat solid tumors. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.

Achilles Therapeutics PLC - American Depositary Shares trades on the NASDAQ stock market under the symbol ACHL.

As of March 4, 2025, ACHL stock price declined to $1.37 with 4,479,034 million shares trading.

ACHL has a beta of 1.10, meaning it tends to be more sensitive to market movements. ACHL has a correlation of 0.04 to the broad based SPY ETF.

ACHL has a market cap of $58.50 million. This is considered a Micro Cap stock.

In the last 3 years, ACHL traded as high as $3.45 and as low as $.63.

ACHL has underperformed the market in the last year with a return of -7.4%, while SPY returned +14.0%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in ACHL shares. However, ACHL has outperformed the market in the last 3 month and 2 week periods, returning +28.6% and -1.4%, while SPY returned -4.7% and -5.7%, respectively. This indicates ACHL has been having a stronger performance recently.

ACHL support price is $1.35 and resistance is $1.41 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ACHL shares will trade within this expected range on the day.